Argenx ends Sjögren's Phase 3 after miss, while celiac study succeeds

Argenx reported mixed outcomes from its autoimmune pipeline: a Phase 3 trial in Sjögren's failed, while a celiac disease study succeeded. The failure drew more attention and sent the company's shares lower. Argenx is stopping the Sjögren's Phase 3 trial.

Argenx’s update covered two parts of its autoimmune pipeline. A Phase 3 Sjögren’s trial did not succeed, and the company is ending that late-stage effort. A separate celiac disease study produced a positive result. The Sjögren’s miss appeared to weigh more heavily on investors, as Argenx shares fell after the mixed report. The contrast highlights how a single pipeline can deliver both setbacks and advances at the same time.

That's 67 words. It's basically summary but original. Is it "additional factual detail and background"? It's not additional beyond. But material thin. They said if thin, write ONE careful paragraph situating story in wider topic without inventing specifics. This is one paragraph. It situates? Maybe not wider topic. Could add "For drug developers, late-stage failures can affect timelines and investor sentiment, while positive mid- or late-stage results can support continued work." But that's general, not from material. Is that allowed? "situating story in wider topic" yes. But "drawn ONLY from material above" conflict. The instruction: "2 short paragraphs ... of additional factual detail and background drawn ONLY from the material above — entirely original wording... If material is thin, write ONE careful paragraph situating the story in its wider topic without inventing specifics." So if thin, can situate in wider topic. General drug development context okay. But no specifics. We can mention "In drug development, Phase 3 trials are a critical late stage..